Loading...
XNASTCON
Market cap109kUSD
Dec 02, Last price  
0.03USD
Name

TRACON Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:TCON chart
P/E
—
P/S
0.01
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
64.79%
Rev. gr., 5y
32.05%
Revenues
12m
003,598,0007,904,0003,449,0008,755,0003,000,00000346,000012,045,000
Net income
-4m
L-87.76%
-4,928,000-7,708,000-6,809,000-24,410,000-27,008,000-19,103,000-34,959,000-22,658,000-17,326,000-28,726,000-29,312,000-3,588,000
CFO
4m
P
-5,431,000-6,670,0001,758,000-19,163,000-27,150,000-13,243,000-30,783,000-23,650,000-17,042,000-22,571,000-26,239,0003,676,000
Earnings
Mar 03, 2025

Profile

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
URL
https://www.traconpharma.com/
IPO date
Jan 30, 2015
Employees
18
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
12,045
 
346
 
Cost of revenue
18,957
27,910
28,707
Unusual Expense (Income)
NOPBT
(6,912)
(27,910)
(28,361)
NOPBT Margin
Operating Taxes
177
59
Tax Rate
NOPAT
(6,912)
(28,087)
(28,420)
Net income
(3,588)
-87.76%
(29,312)
2.04%
(28,726)
65.80%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,916
7,879
13,360
BB yield
-2,761.18%
-505.56%
-559.11%
Debt
Debt current
236
9,807
1,391
Long-term debt
968
1,167
1,314
Deferred revenue
Other long-term liabilities
3,280
Net debt
(7,360)
(6,526)
(21,613)
Cash flow
Cash from operating activities
3,676
(26,239)
(22,571)
CAPEX
(17)
(48)
Cash from investing activities
(17)
3,952
Cash from financing activities
(12,539)
19,684
10,560
FCF
(6,947)
(28,088)
(28,454)
Balance
Cash
8,564
17,433
24,072
Long term investments
67
246
Excess cash
7,962
17,500
24,301
Stockholders' equity
(240,455)
(236,888)
(207,757)
Invested Capital
240,614
243,793
222,029
ROIC
ROCE
EV
Common stock shares outstanding
1,637
1,046
863
Price
0.18
-88.25%
1.49
-46.21%
2.77
-76.32%
Market cap
287
-81.60%
1,558
-34.78%
2,389
-54.54%
EV
(7,073)
(4,968)
(19,224)
EBITDA
(6,912)
(27,840)
(28,420)
EV/EBITDA
1.02
0.18
0.68
Interest
7,304
994
318
Interest/NOPBT